Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic
  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

P3 Health Partners Announces Fourth Quarter and Full Year 2024 Results

Revenue increased 18% year-over-year to $1.50 billion

Affirming 2025 guidance

Management to Host Conference Call and Webcast [March 27, 2025] at 4:30 PM ET

P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient- centered and physician-led population health management company, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and affirmed its 2025 guidance.

“Our business model remains fundamentally strong as we continue to deliver member and top-line growth, quality outcomes, and provider retention,” said Aric Coffman, CEO of P3. “With the $130M+ in identified programmatic opportunities advancing our path to financial sustainability, we remain committed to enabling our payor and provider partners to drive high quality, cost-efficient care and long-term market growth.”

Fourth Quarter 2024 Financial Results

  • Total revenue was $370.7 million, an increase of 7% compared to $346.9 million in the fourth quarter of the prior year
  • Capitated revenue was $367.5 million, an increase of 7% compared to $342.8 million in the fourth quarter of the prior year
  • Gross profit was a loss of $39.5 million, as compared to negative $20.8 million in the fourth quarter of the prior year. Gross profit PMPM was a loss of $103, as compared to a loss of $65 in the fourth quarter of the prior year
  • Medical margin(1) was $7.3 million compared to $9.1 million in the prior year. Medical margin PMPM(1) was $19 compared to a medical margin PMPM of $28 in the prior year
  • Net loss was $129.1 million compared to a net loss of $69.1 million in the fourth quarter of the prior year. Net loss PMPM was $335 compared to a net loss PMPM of $220 in the prior year
  • Adjusted EBITDA loss(1) was $67.6 million compared to $44.3 million in the fourth quarter of the prior year. Adjusted EBITDA loss PMPM(1) was $175 compared to Adjusted EBITDA loss PMPM of $138 in the fourth quarter of the prior year

Full-Year 2024 Financial Results

  • At-risk membership of 123,800, an increase of approximately 14% compared to 108,900 in the prior year(2)
  • Total revenue was $1.50 billion, an increase of 18% compared to $1.27 billion in the prior year
  • Capitated revenue was $1.48 billion, an increase of 18% compared to $1.25 billion in the prior year
  • Gross profit was a loss of $58.9 million, as compared to positive $31.6 million in the prior year. Gross profit PMPM was a loss of $52, compared to a positive $25 PMPM in the prior year
  • Medical margin(1) was $85.5 million, an decrease of 37% compared to $135.1 million in the prior year. Medical margin PMPM(1) was $75, a decrease of 48% compared to a medical margin PMPM of $108 in the prior year
  • Net loss was $310.4 million compared to a net loss of $186.4 million in the prior year
  • Adjusted EBITDA loss(1) was $167.2 million compared to an Adjusted EBITDA loss(1) of $85.5 million in the prior year. Adjusted EBITDA loss PMPM(1) was $147 compared to Adjusted EBITDA loss PMPM(1) of $68 in the prior year

 

Fiscal 2025 Guidance

 

Year Ended December 31, 2025

 

Low

High

At-risk Members

 

109,000

119,000

Total Revenues (in millions)

 

$1,350

$1,500

Medical Margin(1)(3) (in millions)

 

$174

$210

Medical Margin(3) PMPM

 

$133

$147

Adjusted EBITDA(3) (in millions)

 

$(35)

$5

(1)

Adjusted EBITDA, Adjusted EBITDA per member, per month (“PMPM”), medical margin, and medical margin PMPM are non-GAAP financial measures. For reconciliations of these measures to the most directly comparable GAAP measures, if applicable, and more information regarding the Company’s use of non-GAAP financial measures, please see the section titled “Non-GAAP Financial Measures.”

(2)

See “Key Performance Metrics” for additional information on how the Company defines “at-risk members.”

(3)

The Company is not able to provide a quantitative reconciliation of guidance for Adjusted EBITDA, medical margin and medical margin PMPM to net income (loss), gross profit and gross profit PMPM, the most directly comparable GAAP measures, respectively, and has not provided forward-looking guidance for net income (loss), because of the uncertainty around certain items that may impact net income (loss), gross profit (loss) or gross profit (loss) PMPM that are not within our control or cannot be reasonably predicted without unreasonable effort. For more information regarding the non-GAAP financial measures discussed in this press release, please see “Non-GAAP Financial Measures” below.

The foregoing 2025 outlook statement represents management's current estimate as of the date of this release. Actual results may differ materially depending on a number of factors. Investors are urged to read the “Cautionary Note Regarding Forward-Looking Statements” included in this release. Management does not assume any obligation to update these estimates.

Management to Host Conference Call and Webcast on [March 27, 2025] at 4:30 PM ET

Title & Webcast

P3 Health Fourth Quarter and Full Year 2024 Earnings Conference Call

Date & Time

March 27, 2025, 4:30pm Eastern Time

Conference Call Details

Toll-Free 1-833-316-0546 (US)

International 1-412-317-0692

Ask to be joined into the P3 Health Partners call

The conference call will also be webcast live in the “Events & Presentations” section of the Investor page of the P3 website (ir.p3hp.org). The Company’s press release will be available at ir.p3hp.org website in advance of the conference call. An archived recording of the webcast will be available at ir.p3hp.org for a period of 90 days following the conference call.

About P3 Health Partners (NASDAQ: PIII):

P3 Health Partners Inc. is a leading population health management company committed to transforming healthcare by improving the lives of both patients and providers. Founded and led by physicians, P3 has an expansive network of more than 3,100 affiliated primary care providers across the country. Our local teams of health care professionals manage the care of thousands of patients in 27 counties across five states. P3 supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, the P3 care team creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. For more information, visit www.p3hp.org and follow us on @p3healthpartners and Facebook.com/p3healthpartners.

Non-GAAP Financial Measures

In addition to the financial results prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”), this press release contains certain non-GAAP financial measures as defined by the SEC rules, including Adjusted EBITDA and Adjusted EBITDA PMPM, medical margin, and medical margin PMPM. EBITDA is defined as GAAP net income (loss) before (i) interest, (ii) income taxes and (iii) depreciation and amortization. Adjusted EBITDA is defined as EBITDA, further adjusted to exclude the effect of certain supplemental adjustments, such as (i) mark-to-market warrant gain/loss, (ii) premium deficiency reserves, (iii) equity-based compensation expense, (iv) certain transaction and other related costs and (v) certain other items that we believe are not indicative of our core operating performances. Adjusted EBITDA PMPM is defined as Adjusted EBITDA divided by the number of at-risk Medicare members each month divided by the number of months in the period. We believe these non-GAAP financial measures provide an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial measures with other similar companies. Medical margin represents the amount earned from capitation revenue after medical claims expenses are deducted and medical margin PMPM is defined as medical margin divided by the number of Medicare members each month divided by the number of months in the period. Medical claims expenses represent costs incurred for medical services provided to our members. As our platform grows and matures over time, we expect medical margin to increase in absolute dollars; however, medical margin PMPM may vary as the percentage of new members brought onto our platform fluctuates. New membership added to the platform is typically dilutive to medical margin PMPM. We do not consider these non-GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. These non-GAAP financial measures are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-GAAP financial measures. In addition, other companies may calculate non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. The tables at the end of this press release present a reconciliation of Adjusted EBITDA to net income (loss) and Adjusted EBITDA PMPM to net income (loss) PMPM, medical margin to gross profit, and medical margin PMPM to gross profit PMPM, which are the most directly comparable financial measures calculated in accordance with GAAP.

Key Performance Metrics

In addition to our GAAP and non-GAAP financial information, the Company also monitors “at-risk members” to help us evaluate our business, identify trends affecting our business, formulate business plans and make strategic decisions. At-risk membership represents the approximate number of Medicare members for whom we receive a fixed percentage of premium under capitation arrangements as of the end of a particular period.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "anticipate," "believe," "budget," "contemplate," "continue," "could," "envision," "estimate," "expect," "guidance," "indicate," "intend," "may," "might," "plan," "possibly," "potential," "predict," "probably," "pro-forma," "project," "seek," "should," "target," or "will," or the negative or other variations thereof, and similar words or phrases or comparable terminology, are intended to identify forward-looking statements. These forward-looking statements address various matters, including the Company’s future expected growth strategy and operating performance; and the Company’s ability to execute on its identified strategic improvement opportunities, all of which reflect the Company’s expectations based upon currently available information and data. Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected or estimated and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements.

Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in forward-looking statements include, among others, our ability to continue as a going concern; our potential need to raise additional capital to fund our existing operations or develop and commercialize new services or expand our operations; our ability to achieve or maintain profitability; our ability to maintain compliance with our debt covenants in the future, or obtain required waivers from our lenders if future operating performance were to fall below current projections, and if there are material changes to management’s assumptions, we could be required to recognize non-cash charges to operating earnings for goodwill and/or other intangible asset impairment; our ability to identify and develop successful new geographies, physician partners, payors and patients; changes in market or industry conditions, regulatory environment, competitive conditions, and receptivity to our services; our ability to fund our growth and expand our operations; changes in laws and regulations applicable to our business; our ability to maintain our relationships with health plans and other key payors; the impact of fluctuations in risk adjustments; our ability to establish and maintain effective internal controls and the impact of material weaknesses we have identified; our ability to maintain the listing of our securities on Nasdaq; increased labor costs and medical expense; our ability to recruit and retain qualified team members and independent physicians; and the factors described under Part I, Item 1A. “Risk Factors” and Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on [March 27, 2024], and in our subsequent filings with the SEC.

All information in this press release is as of the date hereof, and we undertake no duty to update or revise this information unless required by law. You are cautioned not to place undue reliance on any forward-looking statements contained in this press release.

P3 HEALTH PARTNERS INC. and SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(in thousands, except per share amounts)

(unaudited)

 
 
 

December 31, 2024

December 31, 2023

ASSETS
CURRENT ASSETS:

Cash

$

38,816

 

$

36,320

 

Restricted cash

 

5,286

 

 

4,614

 

Health plan receivable, net of allowance for credit losses of $150

 

121,266

 

 

118,497

 

Clinic fees, insurance and other receivable

 

3,947

 

 

2,973

 

Prepaid expenses and other current assets

 

14,422

 

 

3,613

 

Assets held for sale

 

403

 

 

 

TOTAL CURRENT ASSETS

 

184,140

 

 

166,017

 

Property and equipment, net

 

5,734

 

 

8,686

 

Intangible assets, net

 

574,350

 

 

666,733

 

Other long-term assets

 

19,196

 

 

19,531

 

TOTAL ASSETS (1) $ 783,420 $ 860,967

LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS’ EQUITY

 

 

CURRENT LIABILITIES:

Accounts payable

$

8,442

 

$

8,663

 

Accrued expenses and other current liabilities

 

29,416

 

 

36,884

 

Accrued payroll

 

2,722

 

 

3,506

 

Health plan settlements payable

 

55,565

 

 

34,992

 

Claims payable

 

255,089

 

 

178,009

 

Premium deficiency reserve

 

67,368

 

 

13,670

 

Accrued interest

 

12,460

 

 

23,648

 

Current portion of long-term debt

 

65,000

 

 

 

Short-term debt

 

 

 

 

Liabilities held for sale

 

353

 

 

 

TOTAL CURRENT LIABILITIES

 

496,415

 

 

299,372

 

Operating lease liability

 

11,339

 

 

13,622

 

Warrant liabilities

 

10,312

 

 

1,085

 

Contingent consideration

 

 

 

4,907

 

Long-term debt, net

 

89,824

 

 

108,319

 

Other Long-Term Liabilities

 

26,001

 

 

 

TOTAL LIABILITIES (1)

 

633,891

 

 

427,305

 

COMMITMENTS AND CONTINGENCIES (Note 13)

 

 

MEZZANINE EQUITY:

 

 

Redeemable non-controlling interest

 

73,593

 

 

291,532

 

STOCKHOLDERS’ EQUITY:

 

 

Class A common stock, $0.0001 par value; 800,000 shares authorized; 162,870 and 116,588 shares issued and outstanding as of December 31, 2024 and 2023, respectively

 

 

 

16

 

 

 

 

 

12

 

 

Class V common stock, $0.0001 par value; 205,000 shares authorized; 195,957 and 196,569 shares issued and outstanding as of December 31, 2024 and 2023, respectively

 

 

 

20

 

 

 

 

 

20

 

 

Additional paid in capital

 

579,093

 

 

509,442

 

Accumulated deficit

 

(503,193

)

 

(367,344

)

TOTAL STOCKHOLDERS’ EQUITY

 

75,936

 

 

142,130

 

TOTAL LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS’ EQUITY

$

783,420

$

860,967

(1)

The Company’s consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities (“VIEs”). As discussed in Note 20 “Variable Interest Entities,” P3 LLC is itself a VIE. P3 LLC represents substantially all the assets and liabilities of the Company. As a result, the language and amounts below refer only to VIEs held at the P3 LLC level. The consolidated balance sheets include total assets that can be used only to settle obligations of P3 LLC’s consolidated VIEs totaling $9.3 million and $8.6 million as of December 31, 2024 and 2023, respectively, and total liabilities of P3 LLC’s consolidated VIEs for which creditors do not have recourse to the general credit of the Company totaled $14.9 million and $13.6 million as of December 31, 2024 and 2023, respectively. These VIE assets and liabilities do not include $40.3 million and $44.2 million of net amounts due to affiliates as of December 31, 2024 and 2023, respectively, as these are eliminated in consolidation and not presented within the consolidated balance sheets.

P3 HEALTH PARTNERS INC. and SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

(unaudited)
 

Three Months Ended December 31,

 

Year Ended December 31,

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

OPERATING REVENUE:

Capitated revenue

$

367,456

 

$

342,836

 

$

1,483,602

 

$

1,252,309

 

Other patient service revenue

 

3,230

 

 

4,025

 

 

16,853

 

 

14,066

 

TOTAL OPERATING REVENUE

 

370,686

 

 

346,861

 

 

1,500,455

 

 

1,266,375

 

OPERATING EXPENSE:

 

 

 

 

Medical expense

 

410,224

 

 

367,679

 

 

1,559,372

 

 

1,234,740

 

Premium deficiency reserve

 

37,927

 

 

(3,344

)

 

53,698

 

 

(12,705

)

Corporate, general and administrative expense

 

31,366

 

 

24,431

 

 

112,596

 

 

122,362

 

Sales and marketing expense

 

461

 

 

721

 

 

1,331

 

 

3,233

 

Depreciation and amortization

 

21,153

 

 

21,634

 

 

86,058

 

 

86,675

 

Impairment of Assets Held for Sale

 

8,058

 

 

 

 

8,058

 

 

 

TOTAL OPERATING EXPENSE

 

509,189

 

 

411,121

 

 

1,821,113

 

 

1,434,305

 

OPERATING LOSS

 

(138,503

)

 

(64,260

)

 

(320,658

)

 

(167,930

)

OTHER INCOME (EXPENSE):

 

 

 

 

Interest expense, net

 

(6,834

)

 

(4,046

)

 

(22,173

)

 

(15,985

)

Mark-to-market of stock warrants

 

7,488

 

 

760

 

 

22,114

 

 

433

 

Other

 

384

 

 

206

 

 

1,457

 

 

(249

)

Gain on asset sale, net

 

13,269

 

 

 

 

13,269

 

 

 

TOTAL OTHER (EXPENSE) INCOME

 

14,307

 

 

(3,080

)

 

14,667

 

 

(15,801

)

LOSS BEFORE INCOME TAXES

 

(124,196

)

 

(67,340

)

 

(305,991

)

 

(183,731

)

PROVISION FOR INCOME TAXES

 

(4,952

)

 

(1,767

)

 

(4,387

)

 

(2,695

)

NET LOSS

(129,148

)

(69,107

)

(310,378

)

(186,426

)

LESS: NET LOSS ATTRIBUTABLE TO REDEEMABLE NON-

 

(70,531

)

 

(43,645

)

 

(174,529

)

 

(128,653

)

NET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST

$

(58,617

)

$

(25,462

)

$

(135,849

)

$

(57,773

)

 

 

 

 

 

NET LOSS PER SHARE (Note 16):

 

 

 

 

Basic

 

(0.36

)

 

(0.22

)

 

(0.94

)

 

(0.61

)

Diluted

 

(0.36

)

 

(0.22

)

 

(1.08

)

 

(0.63

)

 

 

 

 

 

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (Note 16):

 

 

 

 

Basic

 

162,634

 

 

115,303

 

 

145,175

 

 

94,889

 

Diluted

 

162,634

 

 

115,303

 

 

146,998

 

 

294,590

 

P3 HEALTH PARTNERS INC. and SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

 

Year Ended December 31,

2024

 

2023

CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss

$

(310,378

)

$

(186,426

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

Depreciation and amortization

 

86,058

 

 

86,675

 

Equity-based compensation

 

5,752

 

 

5,979

 

Amortization of original issue discount and debt issuance costs

 

87

 

 

472

 

Accretion of contingent consideration

 

 

 

113

 

Gain on write off of contingent consideration

 

(4,907

)

 

 

Gain on asset sale

 

(13,269

)

 

 

Impairment of assets held for sale

 

8,058

 

 

 

Mark-to-market adjustment of stock warrants

 

(22,114

)

 

(433

)

Premium deficiency reserve

 

53,698

 

 

(12,705

)

Changes in operating assets and liabilities:

 

 

Health plan receivable

 

(2,769

)

 

(46,555

)

Clinic fees, insurance, and other receivable

 

(990

)

 

4,560

 

Prepaid expenses and other current assets

 

(10,834

)

 

(1,243

)

Other long-term assets

 

(43

)

 

(58

)

Accounts payable, accrued expenses, and other current liabilities

 

(8,101

)

 

15,988

 

Accrued payroll

 

(784

)

 

282

 

Health plan settlements payable

 

20,573

 

 

21,384

 

Claims payable

 

77,080

 

 

26,802

 

Accrued interest

 

7,895

 

 

9,587

 

Other long-term liabilities

 

5,897

 

 

 

Deferred income taxes

 

(1,090

)

 

 

Operating lease liability

 

53

 

 

(450

)

Net cash used in operating activities

 

(110,128

)

 

(76,028

)

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

Purchases of property and equipment

 

 

 

(1,827

)

Proceeds from asset sale

 

14,525

 

 

 

Net cash provided by (used in) investing activities

 

14,525

 

 

(1,827

)

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

Proceeds from long-term debt, net of original issue discount

 

88,057

 

 

14,101

 

Payment of debt issuance costs

 

(103

)

 

(173

)

Proceeds from liability-classified warrants and private placement offering, net of offering costs paid

 

40,496

 

 

86,595

 

Proceeds from at-the-market sales, net of offering costs paid

 

33

 

 

 

Deferred offering costs paid

 

(507

)

 

(175

)

Payment of tax withholdings upon settlement of restricted stock unit awards

 

(103

)

 

(16

)

Repayment of short-term and long-term debt

 

(30,973

)

 

 

Proceeds from short-term debt

 

1,871

 

 

 

Net cash provided by financing activities

 

98,771

 

 

100,332

 

Net change in cash and restricted cash

 

3,168

 

 

22,477

 

Cash and restricted cash, beginning of year

 

40,934

 

 

18,457

 

Cash and restricted cash, end of year

$

44,102

 

$

40,934

 

 

P3 HEALTH PARTNERS INC. and SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)

(in thousands)

 

Year Ended December 31,

 

2024

 

 

2023

 

Supplemental disclosures of cash flow information:

Cash paid for interest

$

14,191

 

$

5,813

 

Cash paid for income taxes

$

5,477

 

$

567

 

Supplemental disclosures of non-cash investing and financing information:

Operating lease liabilities arising from obtaining new right-of-use assets

$

617

 

$

7,222

 

Operating lease liabilities and right-of-use assets reduced due to lease modification or termination

$

(92

)

$

 

Increase in accrued expenses related to debt issuance costs and original issue discount

$

307

 

$

212

 

Increase in accounts payable related to private placement offering costs

$

686

 

$

12

 

Increase in accounts payable related to at-the-market offering costs

$

 

$

19

 

Increase in accrued expenses related to at-the-market offering costs

$

 

$

206

 

Increase in other receivable related to at-the-market sales proceeds

$

 

$

33

 

Restricted stock unit awards issued in satisfaction of executive transaction bonuses

$

 

$

5,000

 

Remeasurement adjustment to redeemable noncontrolling interest resulting from ownership changes

$

(22,831

)

$

(117,860

)

Fair value adjustment to redeemable noncontrolling interest

$

(20,579

)

$

20,579

 

Warrants issued in connection with new debt

$

12,127

 

$

 

Reconciliation of cash and restricted cash:

 

Cash

$

38,816

 

$

36,320

 

Restricted cash

 

5,286

 

 

4,614

 

Total cash and restricted cash

$

44,102

 

$

40,934

 

 

RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA LOSS

(in thousands, except PMPM)

(unaudited)

 

 

Three Months Ended December 31,

Year Ended December 31,

 

2024

 

 

2023

 

 

2024

 

2023

Net loss

$

(129,148

)

$

(69,107

)

$

(310,378

)

$

(186,426

)

Interest expense, net

 

6,834

 

 

4,046

 

 

22,173

 

 

15,985

 

Depreciation and amortization

 

21,153

 

 

21,634

 

 

86,058

 

 

86,675

 

Income tax (benefit) provision

 

4,952

 

 

1,767

 

 

4,387

 

 

2,695

 

Mark-to-market of stock warrants

 

(7,488

)

 

(760

)

 

(22,114

)

 

(433

)

Premium deficiency reserve

 

37,927

 

 

(3,344

)

 

53,698

 

 

(12,705

)

Equity-based compensation

 

721

 

 

1,720

 

 

5,752

 

 

5,979

 

Other(1)

 

(2,533

)

 

(212

)

 

(6,775

)

 

2,656

 

Transaction and other related costs(2)

 

 

 

 

 

 

 

70

 

Adjusted EBITDA loss

$

(67,582

)

$

(44,256

)

$

(167,199

)

$

(85,504

)

Adjusted EBITDA loss PMPM

$

(175

)

$

(138

)

$

(147

)

$

(68

)

_____________________________________________

(1)

 

Other during the year ended December 31, 2024 consisted of (i) interest income, (ii) gain recognized upon the settlement and write-off of contingent consideration related to an acquisition completed in a prior year and (iii) gain recognized on asset sale partially offset by (iv) severance and related expense in connection with our chief executive officer transition (v) loss on impairment on assets held for sale, and (vi) valuation allowance on our notes receivable. Other during the year ended December 31, 2023 consisted of (i) interest income offset by (ii) cybersecurity incident loss, (iii) restructuring and other charges, including severance and benefits paid to employees pursuant to workforce reduction plans, (iv) the disposition of our Pahrump operations, (v) expenses for third-party consultants to assist us with the development, implementation, and documentation of new and enhanced internal controls and processes for compliance with Sarbanes-Oxley Section 404(b), (vi) a legal settlement outside of the ordinary course of business, and (vii) valuation allowance on our notes receivable.

(2)

 

Transaction and other related costs during the year ended December 31, 2023 consisted of legal fees incurred related to acquisition-related litigation.

 

MEDICAL MARGIN

(in thousands, except PMPM)

(unaudited)

 

 

Three Months Ended December 31,

Year Ended December 31,

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Capitated revenue

$

367,456

 

$

342,836

 

$

1,483,602

 

$

1,252,309

 

Less: medical claims expense

 

(360,178

)

 

(333,761

)

 

(1,398,143

)

 

(1,117,258

)

Medical margin

$

7,278

 

$

9,075

 

$

85,459

 

$

135,051

 

Medical margin PMPM

$

19

 

$

28

 

$

75

 

$

108

 

 

RECONCILIATION OF GROSS PROFIT (LOSS) TO MEDICAL MARGIN

(in thousands)

 

 

Three Months Ended December 31,

Year Ended December 31,

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Gross profit (loss)

$

(39,538

)

$

(20,818

)

$

(58,917

)

$

31,635

 

Other patient service revenue

 

(3,230

)

 

(4,025

)

 

(16,853

)

 

(14,066

)

Other medical expense

 

50,046

 

 

33,918

 

 

161,229

 

 

117,482

 

Medical margin

$

7,278

 

$

9,075

 

$

85,459

 

$

135,051

 

 

RECONCILIATION OF TOTAL OPERATING EXPENSE TO ADJUSTED OPERATING EXPENSE

(in thousands)

(unaudited)

 

 

Three Months Ended December 31,

Year Ended December 31,

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Total operating expense

$

509,189

 

$

411,121

 

$

1,821,113

 

$

1,434,305

 

Medical expense

 

(410,224

)

 

(367,679

)

 

(1,559,372

)

 

(1,234,740

)

Depreciation and amortization

 

(21,153

)

 

(21,634

)

 

(86,058

)

 

(86,675

)

Premium deficiency reserve

 

(37,927

)

 

3,344

 

 

(53,698

)

 

12,705

 

Equity-based compensation

 

(721

)

 

(1,720

)

 

(5,752

)

 

(5,979

)

Other

 

2,533

 

 

212

 

 

6,775

 

 

(2,656

)

Transaction and other related costs

 

 

 

 

 

 

 

(70

)

Adjusted operating expense

$

41,697

 

$

23,644

 

$

123,008

 

$

116,890

 

 

Contacts

Ryan Halsted

Investor Relations

Gilmartin Group

ir@p3hp.org

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.